Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

Now Viewing

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

The video discusses best practices for managing patients on bispecific antibody therapy. Haumschild highlights the importance of after-hours care for handling adverse events or urgent patient issues. Hanna outlines the protocol his clinic has established to educate on-call physicians on assessing and triaging bispecific therapy complications, as well as transferring patients to partner hospitals with experience managing cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. He emphasizes the value of preemptive communication and collaboration between community practices and academic medical centers. Chang suggests additional best practices for academic and community collaboration, including establishing clear communication channels, holding regular case discussions, developing standardized treatment protocols, sharing educational materials and guidelines, and organizing joint tumor board meetings. She notes that such coordination can expand patient access and clinical trial enrollment. The discussion centers on how strong partnerships between different care settings can optimize patient outcomes with emerging bispecific therapies.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.